Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CELSA, Ciro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.956
AS - Asia 1.883
EU - Europa 1.829
SA - Sud America 424
AF - Africa 53
OC - Oceania 8
Totale 7.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.883
SG - Singapore 800
IT - Italia 490
CN - Cina 454
RU - Federazione Russa 434
BR - Brasile 346
HK - Hong Kong 241
DE - Germania 234
PL - Polonia 217
VN - Vietnam 155
FI - Finlandia 93
GB - Regno Unito 89
FR - Francia 50
IN - India 44
AT - Austria 42
CA - Canada 37
SE - Svezia 31
TR - Turchia 30
IE - Irlanda 29
ES - Italia 28
AR - Argentina 26
MX - Messico 26
BD - Bangladesh 25
JP - Giappone 22
NL - Olanda 20
EC - Ecuador 17
IQ - Iraq 16
ZA - Sudafrica 16
CI - Costa d'Avorio 15
RO - Romania 14
PY - Paraguay 12
VE - Venezuela 12
UZ - Uzbekistan 11
KR - Corea 10
LT - Lituania 10
BE - Belgio 9
ID - Indonesia 8
MY - Malesia 8
UA - Ucraina 8
AU - Australia 7
PK - Pakistan 7
CH - Svizzera 6
CO - Colombia 6
IL - Israele 6
MA - Marocco 6
AE - Emirati Arabi Uniti 4
AL - Albania 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
AZ - Azerbaigian 3
GE - Georgia 3
HU - Ungheria 3
JM - Giamaica 3
NO - Norvegia 3
NP - Nepal 3
OM - Oman 3
PT - Portogallo 3
SA - Arabia Saudita 3
TH - Thailandia 3
TN - Tunisia 3
TW - Taiwan 3
BS - Bahamas 2
CL - Cile 2
LB - Libano 2
LV - Lettonia 2
NG - Nigeria 2
NI - Nicaragua 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
BG - Bulgaria 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GR - Grecia 1
HN - Honduras 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MG - Madagascar 1
MM - Myanmar 1
NZ - Nuova Zelanda 1
PH - Filippine 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 7.153
Salva come PNG Salva come JPEG
Città #
Ashburn 511
Singapore 491
Chandler 277
Hong Kong 231
Fairfield 211
Zgierz 192
Moscow 139
Palermo 113
New York 110
Beijing 96
Hefei 84
Woodbridge 83
Houston 81
Los Angeles 79
Helsinki 70
Ann Arbor 68
Wilmington 68
Seattle 67
The Dalles 67
Altamura 63
Santa Clara 63
Ho Chi Minh City 61
Medford 58
Dallas 46
Cambridge 45
Rome 45
Lawrence 36
Princeton 36
Nuremberg 34
São Paulo 30
Dublin 29
San Jose 29
Hanoi 28
Ludwigshafen am Rhein 28
Bremen 27
London 26
Des Moines 25
Milan 24
Orem 24
Buffalo 23
Frankfurt am Main 23
Warsaw 22
San Diego 21
Vienna 20
Brooklyn 18
Montreal 18
Lappeenranta 17
Tokyo 17
Chicago 16
Denver 16
Abidjan 15
Poplar 15
Ankara 13
Redondo Beach 13
Stockholm 13
Chennai 12
Phoenix 12
West Jordan 12
Columbus 11
Johannesburg 11
Tashkent 10
Belo Horizonte 9
Bologna 9
Central 9
Mexico City 9
Rio de Janeiro 9
Amsterdam 8
Brasília 8
Brussels 8
Cordova 8
Falkenstein 8
Florence 8
Krefeld 8
Munich 8
Venice 8
Atlanta 7
Biên Hòa 7
Boardman 7
Da Nang 7
Guangzhou 7
Haiphong 7
Hải Dương 7
Nanjing 7
Pune 7
Querétaro 7
Tianjin 7
Washington 7
Asunción 6
Cagliari 6
Changsha 6
Dhaka 6
Düsseldorf 6
Jinan 6
Manchester 6
Quito 6
Salt Lake City 6
Tampa 6
Baghdad 5
Dearborn 5
Erbil 5
Totale 4.419
Salva come PNG Salva come JPEG
Nome #
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 238
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 227
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 203
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 175
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 164
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 164
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 162
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 155
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 152
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 149
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 144
Biochemical biomarkers of NAFLD/NASH 135
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 134
Systemic therapies for hepatocellular carcinoma: The present and the future 133
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 121
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 118
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 118
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 117
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 114
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 112
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 111
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 110
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 109
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 108
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 106
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 104
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 102
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 100
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 100
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 99
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 98
Biliary complications after liver transplantation: current perspectives and future strategies 92
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 91
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 90
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 90
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 89
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 88
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 88
Reply 87
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 87
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 87
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 84
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 83
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 82
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 78
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 76
Reply 75
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 71
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 70
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 68
Identification of clinical phenotypes and related survival in patients with large hccs 67
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 66
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 66
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 65
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 65
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death 63
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 63
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 62
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 62
The Application of Large Language Models in Gastroenterology: A Review of the Literature 60
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 60
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study 59
The price and value of therapeutic synergy in liver cancer 54
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice 50
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 50
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 50
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 50
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 49
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 49
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 49
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 49
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 46
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 46
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 44
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 43
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 43
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 42
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 41
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis 40
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 38
Expert opinion vs. meta-analysis: To be or not to be? 37
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 36
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 36
Reply to: “irLI or not irLI: That is the question” 33
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma 32
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 32
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis 28
354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab 23
Hepatocellular carcinoma in people living with HIV 21
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma 20
The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives 19
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis 17
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 16
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 10
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 10
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 9
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT) 8
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 8
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 8
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 8
Totale 7.760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021227 0 0 0 0 0 0 50 29 51 23 39 35
2021/2022534 50 36 16 17 5 14 10 158 70 32 32 94
2022/2023923 60 165 8 112 82 103 89 73 159 10 35 27
2023/2024550 24 54 36 43 19 153 59 17 17 29 32 67
2024/20251.768 35 125 217 131 31 140 146 82 96 193 229 343
2025/20263.328 417 165 393 679 611 991 72 0 0 0 0 0
Totale 7.783